Released Nov 12, 2026, before the open
10-Q filed Nov 12, 2026, 43 days after period end · 0001919246-26-000135
• Zelsuvmi® net product revenue was $15.2 million in the third quarter of 2026, up 114% from $7.1 million in the third quarter of 2025, driven by strong utilization of Zelsuvmi by health care providers, increased formulary position, and optimized gross-to-net deductions.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $15.40M | $7.41M | — | — |
| Net Income | -$7.90M | -$16.24M |
Pelthos Therapeutics Inc. · CIK 1919246 · Engraved from SEC EDGAR
| -$1.70M |
| -$1.42M |
| EPS Diluted | -$2.04 | -$5.30 | -$2.93 | — |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zelsuvmi net product revenue was $15.2 million in the third quarter of 2026, up 114% from $7.1 million a year earlier, and the net loss was $(7.9) million.¶2¶3
On October 30, 2026, Pelthos entered into a definitive merger agreement with Castle Creek Biosciences, Inc., with closing expected by the end of the first quarter of 2027.¶4¶5
On October 30, 2026, Pelthos entered into an amended Venture Loan and Security Agreement with Horizon Technology Finance providing up to $50.0 million, with $40.0 million outstanding after an additional $10.0 million draw.¶6
Pelthos reported a cash balance of $17.7 million as of September 30, 2026, not including an additional $10.0 million borrowed from Horizon on October 30, 2026.¶7
Adjusted EBITDA for the third quarter of 2026 was $(5.6) million, compared with $(10.4) million for the third quarter of 2025.¶8